Roivant Sciences Ltd. Common Shares (ROIV) is a publicly traded Healthcare sector company. As of November 18, 2026, ROIV trades at $38.74 with a market cap of $28.05B and a P/E ratio of -83.81. ROIV moved +0.06% today. Year to date, ROIV is +81.85%; over the trailing twelve months it is +88.76%. Its 52-week range spans $8.73 to $42.50. Analyst consensus is strong buy with an average price target of $49.18. Rallies surfaces ROIV's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for ROIV, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $38.74 |
| Market Cap | $28.05B |
| P/E Ratio | -83.81 |
| EPS | $-0.43 |
| Dividend Yield | 0.00% |
| 52-Week High | $42.50 |
| 52-Week Low | $8.73 |
| Volume | 2.87M |
| Avg Volume | 0 |
| Revenue (TTM) | $8.26M |
| Net Income | $-397.91M |
| Gross Margin | 0.00% |
12 analysts cover ROIV: 0 strong buy, 10 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $49.18.